ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2012
Photochemical release of methotrexate from folate receptor-targeting PAMAM dendrimer nanoconjugate.
Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 54 citations in OpenAlex.
- Control of Gemcitabine Activity With Blue and Red Light.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- PAMAM dendrimers based co-delivery of methotrexate and berberine for targeting of Hela cancer cells.Toxicology reports · 2024Article
- NIR-Responsive Methotrexate-Modified Iron Selenide Nanorods for Synergistic Magnetic Hyperthermic, Photothermal, and Chemodynamic Therapy.ACS applied materials & interfaces · 2024Article
- Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Review
- PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy.Applied materials today · 2018Article
- Light induced drug release from a folic acid-drug conjugate.Bioorganic & medicinal chemistry letters · 2017Article
- A Thioacetal Photocage Designed for Dual Release: Application in the Quantitation of Therapeutic Release by Synchronous Reporter Decaging.Chembiochem : a European journal of chemical biology · 2017Article
- Light-controlled active release of photocaged ciprofloxacin for lipopolysaccharide-targeted drug delivery using dendrimer conjugates.Chemical communications (Cambridge, England) · 2016Article
- Mechanisms and implications of dual-acting methotrexate in folate-targeted nanotherapeutic delivery.International journal of molecular sciences · 2015Review
- Effect of methotrexate conjugated PAMAM dendrimers on the viability of MES-SA uterine cancer cells.Journal of pharmacy & bioallied sciences · 2014Article
- Folic acid conjugated cross-linked acrylic polymer (FA-CLAP) hydrogel for site specific delivery of hydrophobic drugs to cancer cells.Journal of nanobiotechnology · 2014Article
- Synthesis of a photocaged tamoxifen for light-dependent activation of Cre-ER recombinase-driven gene modification.Chemical communications (Cambridge, England) · 2013Article
- Design and in vitro validation of multivalent dendrimer methotrexates as a folate-targeting anticancer therapeutic.Current pharmaceutical design · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Nanoparticle (NP)-based targeted drug delivery involves cell-specific targeting followed by a subsequent therapeutic action from the therapeutic carried by the NP system. NPs conjugated with methotrexate (MTX), a potent inhibitor of dihydrofolate reductase (DHFR) localized in cytosol, have been under investigation as a delivery system to target cancer cells to enhance the therapeutic index of methotrexate, which is otherwise non-selectively cytotoxic. Despite improved therapeutic activity from MTX-conjugated NPs in vitro and in vivo, the therapeutic action of these conjugates following cellular entry is poorly understood; in particular it is unclear whether the therapeutic activity requires release of the MTX. This study investigates whether MTX must be released from a nanoparticle in order to achieve the therapeutic activity. We report herein light-controlled release of methotrexate from a dendrimer-based conjugate and provide evidence suggesting that MTX still attached to the nanoconjugate system is fully able to inhibit the activity of its enzyme target and the growth of cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.